Home » Navidea Biopharmaceuticals Announces Completion of Additional Fundamental Clinical Trial for Radiopharmaceutical Agent, NAV4694, in Alzheimer’s Disease
Navidea Biopharmaceuticals Announces Completion of Additional Fundamental Clinical Trial for Radiopharmaceutical Agent, NAV4694, in Alzheimer’s Disease
Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the completion of a study of its novel radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral β-amyloid in diagnosing Alzheimer’s disease (AD).
Yahoo! Medical News
Yahoo! Medical News
Upcoming Events
-
07May
-
14May
-
30May